Share-based Payment Arrangement, Expense of Fusion Pharmaceuticals Inc. from 30 Jun 2019 to 31 Mar 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Fusion Pharmaceuticals Inc. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 30 Jun 2019 to 31 Mar 2024.
  • Fusion Pharmaceuticals Inc. Share-based Payment Arrangement, Expense for the quarter ending 31 Mar 2024 was $4,517,000, a 43% increase year-over-year.
  • Fusion Pharmaceuticals Inc. Share-based Payment Arrangement, Expense for the twelve months ending 31 Mar 2024 was $13,812,000, a 22% increase year-over-year.
  • Fusion Pharmaceuticals Inc. annual Share-based Payment Arrangement, Expense for 2023 was $12,444,000, a 15% increase from 2022.
  • Fusion Pharmaceuticals Inc. annual Share-based Payment Arrangement, Expense for 2022 was $10,844,000, a 26% increase from 2021.
  • Fusion Pharmaceuticals Inc. annual Share-based Payment Arrangement, Expense for 2021 was $8,603,000, a 155% increase from 2020.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

Fusion Pharmaceuticals Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q1 2024 $13,812,000 $4,517,000 +$1,368,000 +43% 01 Jan 2024 31 Mar 2024 10-Q 07 May 2024 2024 Q1
Q4 2023 $12,444,000 $3,255,000 +$477,000 +17% 01 Oct 2023 31 Dec 2023 10-K 20 Mar 2024 2023 Q4
Q3 2023 $11,967,000 $2,994,000 +$297,000 +11% 01 Jul 2023 30 Sep 2023 10-Q 07 Nov 2023 2023 Q3
Q2 2023 $11,670,000 $3,046,000 +$310,000 +11% 01 Apr 2023 30 Jun 2023 10-Q 08 Aug 2023 2023 Q2
Q1 2023 $11,360,000 $3,149,000 +$516,000 +20% 01 Jan 2023 31 Mar 2023 10-Q 07 May 2024 2024 Q1
Q4 2022 $10,844,000 $2,778,000 +$412,000 +17% 01 Oct 2022 31 Dec 2022 10-K 20 Mar 2024 2023 Q4
Q3 2022 $10,432,000 $2,697,000 +$323,000 +14% 01 Jul 2022 30 Sep 2022 10-Q 07 Nov 2023 2023 Q3
Q2 2022 $10,109,000 $2,736,000 +$591,000 +28% 01 Apr 2022 30 Jun 2022 10-Q 08 Aug 2023 2023 Q2
Q1 2022 $9,518,000 $2,633,000 +$915,000 +53% 01 Jan 2022 31 Mar 2022 10-Q 11 May 2023 2023 Q1
Q4 2021 $8,603,000 $2,366,000 +$1,023,000 +76% 01 Oct 2021 31 Dec 2021 10-K 16 Mar 2023 2022 Q4
Q3 2021 $7,580,000 $2,374,000 +$1,133,000 +91% 01 Jul 2021 30 Sep 2021 10-Q 08 Nov 2022 2022 Q3
Q2 2021 $6,447,000 $2,145,000 +$1,719,000 +404% 01 Apr 2021 30 Jun 2021 10-Q 09 Aug 2022 2022 Q2
Q1 2021 $4,728,000 $1,718,000 +$1,360,000 +380% 01 Jan 2021 31 Mar 2021 10-Q 10 May 2022 2022 Q1
Q4 2020 $3,368,000 $1,343,000 01 Oct 2020 31 Dec 2020 10-K 17 Mar 2022 2021 Q4
Q3 2020 $1,241,000 +$1,103,000 +799% 01 Jul 2020 30 Sep 2020 10-Q 09 Nov 2021 2021 Q3
Q2 2020 $426,000 +$338,000 +384% 01 Apr 2020 30 Jun 2020 10-Q 10 Aug 2021 2021 Q2
Q1 2020 $358,000 01 Jan 2020 31 Mar 2020 10-Q 11 May 2021 2021 Q1
Q3 2019 $138,000 01 Jul 2019 30 Sep 2019 10-Q 10 Nov 2020 2020 Q3
Q2 2019 $88,000 01 Apr 2019 30 Jun 2019 10-Q 11 Aug 2020 2020 Q2

Fusion Pharmaceuticals Inc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2023 $12,444,000 +$1,600,000 +15% 01 Jan 2023 31 Dec 2023 10-K 20 Mar 2024 2023 FY
2022 $10,844,000 +$2,241,000 +26% 01 Jan 2022 31 Dec 2022 10-K 20 Mar 2024 2023 FY
2021 $8,603,000 +$5,235,000 +155% 01 Jan 2021 31 Dec 2021 10-K 16 Mar 2023 2022 FY
2020 $3,368,000 +$2,750,000 +445% 01 Jan 2020 31 Dec 2020 10-K 17 Mar 2022 2021 FY
2019 $618,000 01 Jan 2019 31 Dec 2019 10-K 25 Mar 2021 2020 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.